Data from an investigational, open-label, randomized study assessing extended dosing regimens of PROCRIT® (Epoetin alfa) in treating anemia in subjects with Stages 3 - 4 chronic kidney disease (CKD) were presented at the American Society of Nephrology 41st Annual Meeting.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.